{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:26:42Z","timestamp":1776846402287,"version":"3.51.2"},"reference-count":19,"publisher":"BMJ","issue":"14","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience worsening cardiac disease (WCD) despite disease-modifying treatment. However, a strict definition is lacking. Recent studies have shown that N-terminal pro-B-natriuretic peptide (NT-proBNP increase), or intensification of oral diuretics, is associated with increased mortality risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To describe the pattern of WCD at 1 year in patients with ATTR-CM on tafamidis and explore the association with mortality and cardiovascular (CV) hospitalisation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients diagnosed with ATTR-CM at Columbia University after 2018 who were treated with tafamidis were enrolled in the study. WCD was defined as: increase in NT-proBNP &gt;700\u2009pg\/mL and &gt;30% from baseline or oral diuretic intensification (ODI) or both. Survival and CV hospitalisation risk analysis was performed using Kaplan-Meier curves, Cox regression and competing risk regression adjusted for age, genotype and disease severity by the National Amyloidosis Centre (NAC) stage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 238 patients were enrolled, 100 (42%) of whom showed WCD at 1 year. WCD was associated with increased mortality risk (log rank, p&lt;0.0001, HR=1.91 (1.10\u20133.32), p=0.023, after adjustment for age, genotype and baseline NAC stage). In competing risk analysis, WCD was associated with increased risk for CV-related hospitalisation (HR=1.8 (1.17\u20132.99, p=0.009)) after adjustment for age, genotype and baseline NAC stage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>NT-proBNP increase and ODI can serve as markers of WCD and predict mortality and CV hospitalisations in a cohort of patients taking tafamidis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2024-324826","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T01:49:04Z","timestamp":1742780944000},"page":"651-656","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis"],"prefix":"10.1136","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-2912","authenticated-orcid":false,"given":"Dimitrios","family":"Bampatsias","sequence":"first","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdirahman","family":"Wardhere","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Zeldin","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonsina","family":"Mirabal-Santos","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel Y","family":"Weinsaft","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana C","family":"Levy","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dia","family":"Smiley","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio L","family":"Teruya","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew S","family":"Maurer","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"2025092002265444000_111.14.651.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"2025092002265444000_111.14.651.2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.4147"},{"key":"2025092002265444000_111.14.651.3","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319063"},{"key":"2025092002265444000_111.14.651.4","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14380"},{"key":"2025092002265444000_111.14.651.5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214868","article-title":"Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment","volume":"10","author":"Oghina","year":"2021","journal-title":"J Clin Med"},{"key":"2025092002265444000_111.14.651.6","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2198"},{"key":"2025092002265444000_111.14.651.7","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2024.2376202"},{"key":"2025092002265444000_111.14.651.8","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025092002265444000_111.14.651.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"2025092002265444000_111.14.651.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.06.007"},{"key":"2025092002265444000_111.14.651.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.02.014"},{"key":"2025092002265444000_111.14.651.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.08.009"},{"key":"2025092002265444000_111.14.651.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"2025092002265444000_111.14.651.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2305434"},{"key":"2025092002265444000_111.14.651.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"},{"key":"2025092002265444000_111.14.651.16","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025092002265444000_111.14.651.17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3198"},{"key":"2025092002265444000_111.14.651.18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad347"},{"key":"2025092002265444000_111.14.651.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.04.011"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2024-324826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:27:04Z","timestamp":1758360424000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2024-324826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":19,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,6,26]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/heartjnl-2024-324826"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2024-324826","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]}}}